GC c.661_663del ;(p.S221del)

Variant ID: 4-72629163-GTGA-G

NM_000583.3(GC):c.661_663del;(p.S221del)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Jang, H Josh HJ; Hostetter, Galen G; MacFarlane, Alexander W AW; Madaj, Zachary Z; Ross, Eric A EA; Hinoue, Toshinori T; Kulchycki, Justin R JR; Burgos, Ryan S RS; Tafseer, Mahvish M; Alpaugh, R Katherine RK; Schwebel, Candice L CL; Kokate, Rutika R; Geynisman, Daniel M DM; Zibelman, Matthew R MR; Ghatalia, Pooja P; Nichols, Peter W PW; Chung, Woonbok W; Madzo, Jozef J; Hahn, Noah M NM; Quinn, David I DI; Issa, Jean-Pierre J JJ; Topper, Michael J MJ; Baylin, Stephen B SB; Shen, Hui H; Campbell, Kerry S KS; Jones, Peter A PA; Plimack, Elizabeth R ER
Publication Date: 2023-03-16

Variant appearance in text: GC: S221del
PubMed Link: 36928921
Variant Present in the following documents:
  • ccr-22-3642_supplementary_tables_1_suppts1.xlsx, sheet 3
View BVdb publication page



Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.

Medical Oncology (Northwood, London, England)
Vietri, Maria Teresa MT; D'Elia, Giovanna G; Caliendo, Gemma G; Casamassimi, Amelia A; Federico, Alessandro A; Passariello, Luana L; Cioffi, Michele M; Molinari, Anna Maria AM
Publication Date: 2021-01-23

Variant appearance in text: GC: S221del
PubMed Link: 33484353
Variant Present in the following documents:
  • 12032_2021_Article_1454.pdf
View BVdb publication page